Brentuximab induced CD30+ cutaneous lymphoma responded to anti‐PD1 treatment

Abstract

Over the last decade major efforts have been made for the optimization of immune‐directed therapies against cancer. Regarding cutaneous lymphomas (CTCLs), brentuximab (BV) has been recently approved by FDA and EMA for the treatment of primary cutaneous anaplastic large cell lymphoma as well as CD30‐expressing mycosis fungoides, based on the ALCANZA trial favorable results. Concurrently, immune checkpoint inhibition has been shown to be of great value in the treatment of solid tumors and with promising results in a range of hematologic malignancies, however relevant data concerning CTCLs' treatment remain inconclusive.

This article is protected by copyright. All rights reserved.

https://ift.tt/2E5Z3SC